Azido Or Sulfonyl Attached Directly To The Tricyclo Ring System By Nonionic Bonding (e.g., Carbazole Sulfonic Acid, Etc.) Patents (Class 548/443)
  • Publication number: 20150044293
    Abstract: Radioprotector compounds including 3,3?-diindolylmethane (DIM) analogs, are provided. Further provided are methods for their use in reducing or preventing radiation damage, killing a tumor cell and protecting a non-tumor cell, and treating cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Applicant: Georgetown University
    Inventors: Eliot M. Rosen, Milton Brown, Saijun Fan, Thomas Walls, Kathryn E. Ditmer
  • Publication number: 20130040977
    Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 14, 2013
    Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
  • Publication number: 20130020565
    Abstract: Provided is a material for an organic electroluminescence device having a specific structure in which a dibenzothiophenyl group or a carbazolyl group is bonded to a carbazolyl group at its N-position (9-position) directly or through a linking group. Further provided is an organic electroluminescence device including one or more organic thin film layers including a light emitting layer between a cathode and an anode, in which at least one organic thin film layer contains the material for an organic electroluminescence device of the present invention.
    Type: Application
    Filed: March 29, 2011
    Publication date: January 24, 2013
    Applicant: IDEMITSU KOSAN CO., LTD.
    Inventors: Masaki Numata, Hideaki Nagashima
  • Patent number: 7618994
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: November 17, 2009
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Patent number: 7449573
    Abstract: A compound which generates a sulfonic acid having one or more —SO3H groups and one or more —SO2— bonds upon irradiation with an actinic ray or a radiation; a photosensitive composition containing the compound; and a method of pattern formation with the photosensitive composition.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: November 11, 2008
    Assignee: FUJIFILM Corporation
    Inventors: Kunihiko Kodama, Kenji Wada, Kaoru Iwato
  • Publication number: 20080146810
    Abstract: The present invention relates to novel tricyclic compounds useful for the treatment of inflammatory conditions, diseases of the central nervous and insulin resistant diabetes.
    Type: Application
    Filed: June 27, 2007
    Publication date: June 19, 2008
    Inventors: Gopalan Balasubramanian, Laxmikant A. Gharat, Aftab D. Lakdawala, Raghu R. Anupindi
  • Patent number: 7317036
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: January 8, 2008
    Assignee: Merck Frosst Canada & Co.
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Patent number: 7019022
    Abstract: The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: March 28, 2006
    Assignee: Merck Frosst Canada & Co.
    Inventors: Christian Beaulieu, Daniel Guay, Zhaoyin Wang, Robert Zamboni
  • Patent number: 6833387
    Abstract: The use of a 3-substituted indole compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof; X is CH2 or SO2 and R1, R2, R3, R4, R5, R6 and R7 are certain specified organic moieties, for use in the preparation of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis. Pharmaceutical compositions containing certain compounds of formula (I) and novel compounds of formula (I) are also described and claimed.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: December 21, 2004
    Assignee: AstraZeneca AB
    Inventors: Alan W. Faull, Jason Kettle
  • Patent number: 6620835
    Abstract: The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: September 16, 2003
    Assignee: Warner-Lambert Company
    Inventors: Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic, Andrew David White
  • Patent number: 6603020
    Abstract: The present invention relates to fluorescent diketopyrrolopyrroles of formula I and processes for its preparation, its uses and compositions comprising the compounds of formula I.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: August 5, 2003
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Robert Moretti, Zhimin Hao, Hiroshi Yamamoto
  • Publication number: 20020169164
    Abstract: Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.
    Type: Application
    Filed: March 27, 2002
    Publication date: November 14, 2002
    Applicant: Warner-Lambert Company
    Inventors: Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic
  • Publication number: 20010036958
    Abstract: N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Application
    Filed: December 27, 2000
    Publication date: November 1, 2001
    Inventors: Ming Fai Chan, Bore Gowda Raju, Adam Kois, Erik Joel Verner, Chengde Wu, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji, Kalyanaraman Ramnarayan
  • Patent number: 6194439
    Abstract: Certain tricyclic polyhydroxylic compounds, and their pharmaceutically-acceptable salts, are inhibitors of tyrosine kinase enzymes, and so are useful for the control of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis).
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: February 27, 2001
    Assignee: Pfizer Inc.
    Inventor: Robert L. Dow
  • Patent number: 5877199
    Abstract: A compound of formula (I): ##STR1## wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are each hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, alkyl, haloalkyl, alkylthio, a protected or unprotected carboxyl, a protected or unprotected sulfonamide, or tetrazol; one of R.sup.1 and R.sup.2 is hydrogen, alkyl, aryl, aralkyl, oxazolyl, or a protected or unprotected carboxyl and the other of R.sup.1 and R.sup.2 is hydrogen, alkyl, aryl or aralkyl; and R.sup.3 is hydrogen or an amino protecting group, and pharmaceutically acceptable salts or esters thereof. The compounds are effective for treating dementia, Alzheimer's disease and delirium and are effective as sedatives.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: March 2, 1999
    Assignee: Sankyo Company, Limited
    Inventors: Nigel Birdsall, Sebastian Lazareno, Syunji Naruto, Masahiko Sugimoto, Kazuo Koyama, Shinji Marumoto
  • Patent number: 5824699
    Abstract: This invention provides compounds of formula I having the structure ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are, each, independently, hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aralkoxy, trifluroalkoxy, alkanoyloxy, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino, alkanamido, or alkanesulfonamido;R.sub.5 is hydrogen, alkyl, alkenyl, alkoxyalkyl or alkylcycloalkyl;R.sub.6 is hydrogen, alkyl or alkenyl;X is oxygen or carbon;A is oxygen or NZ;Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1-6 carbon atoms;or a pharmaceutically acceptable salt thereof, which are useful in the treatment of arthritic disorders, colorectal cancer, and Alzheimer's disease.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: October 20, 1998
    Assignee: American Home Products Corporation
    Inventors: Anthony F. Kreft, Craig E. Caufield, Amedeo A. Failli, Thomas J. Caggiano, Alexander A. Greenfield, Dennis M. Kubrak
  • Patent number: 5519134
    Abstract: Novel pyrrolidine monomers bearing various functional groups are used to prepare oligomeric structures. The pyrrolidine monomers can be joined via standard phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.
    Type: Grant
    Filed: January 11, 1994
    Date of Patent: May 21, 1996
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Oscar L. Acevedo, Normand Hebert
  • Patent number: 5516789
    Abstract: Compounds having the structure ##STR1## or a pharmaceutically acceptable salt thereof have activity as inhibitors of cylooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B.sub.4, C.sub.4, D.sub.4, and E.sub.4 and cylooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optinally substituted carbocyclic aryl, (b) optinally substituted furyl, (c) optinally substituted benzo[b]furyl, (d) optinally substituted thienyl, (e) optinally substituted pyridyloxy, (f) optinally substituted pyridylalkyl, (g) optinally substituted benzo[b]thienyl, (h) optinally substituted pyridyl, (i) optinally substituted quinolyl, and (j) optinally substituted indolyl; X is selected from (a) optionally substituted alkyl, (b) optinally substituted alkenyl, and (c) optinally substituted alkynyl; R.sup.1 and R.sup.
    Type: Grant
    Filed: April 12, 1995
    Date of Patent: May 14, 1996
    Assignee: Abbott Laboratories
    Inventors: Clint D. W. Brooks, Andrew O. Stewart, Anwer Basha, Randy L. Bell
  • Patent number: 5508396
    Abstract: A process for preparing an N-alkyllactam, comprising the steps of:(a) reacting a lactam with an alkali metal alkoxide at C. and removing the alcohol formed by distillation;(b) reacting the product from step (a), if desired in a mixture with the product from step (e), with an alkyl halide in a solvent which is(i) an ethylene glycol dialkyl ether of the formula R--O--(CH.sub.2 --CH.sub.2 --O).sub.m R, where R in C.sub.1 -C.sub.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: April 16, 1996
    Assignee: Huels Aktiengesellschaft
    Inventor: Klaus-Dieter Steffen
  • Patent number: 5444495
    Abstract: A MUSE-NTSC converter of a relatively simple and small scale circuit design. An oscillation signal from a 28.63636 MHz oscillator (20) is eight times as large as a subcarrier frequency fsc. A Y image processing circuit (17) and a chroma encoder (18) can perform various kinds of processing, such as dividing a frequency of the oscillation signal from the 28.63636 MHz oscillator (20) and the like, to produce a subcarrier frequency. A signal separating circuit (3') receives the oscillation signal from the 28.63636 MHz oscillator (20) as a single system clock and performs some kinds of signal processing which vary from a full wide mode to a zoom mode. Thus, in performing PLL on system clocks in the MUSE mode and the NTSC mode, there may be only one PLL circuit (21) for synchronizing an oscillation signal from a 32.4 MHz oscillator (19) and the oscillation signal from the 28.63636 MHz oscillator (20) in phase.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: August 22, 1995
    Assignee: Mitsubishi Denki Kabushiki Kaisha
    Inventors: Akiko Takahama, Masahiko Nakamura, Hiroyuki Nakayama, Eiji Arita, Yoichi Asamoto
  • Patent number: 5204374
    Abstract: New cycloalkano[b]dihydroindoles and -indolesulphonamides, substituted by heterocycles, of the formula (I) ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are identical or different andrepresent hydrogen, nitro, cyano, halogen, trifluoromethyl, carboxyl, hydroxyl or trifluoromethoxy, orrepresent a group of the formula --S(O).sub.w R.sup.5, in whichR.sup.5 denotes alkyl or optionally substituted aryl,w denotes the number 0, 1 or 2, orrepresents alkoxy or alkoxycarbonyl, or benzyloxy, orrepresents a group of the formula --NR.sup.6 R.sup.7, in whichR.sup.6 and R.sup.7 are identical or different anddenote hydrogen, alkyl or acyl ordenote aryl, ordenote a group of the formula --S(O).sub.w R.sup.5, in which R.sup.
    Type: Grant
    Filed: April 3, 1991
    Date of Patent: April 20, 1993
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich E. Muller, Ulrich Rosentreter, Ulrich Niewohner, Elisabeth Perzborn, Erwin Bischoff, Hans-Georg Dellweg, Peter Norman, Nigel J. Cuthbert, Hilary P. Francis
  • Patent number: 5102905
    Abstract: The invention concerns heterocyclic nitromethane derivatives of the formula 1 as defined hereinafter (and their non-toxic salts) wherein the heterocyclic moiety Q is thienyl, benzothienyl or dibenzothienyl and may bear a wide variety of optional substituents, together with pharmaceutical compositions containing them. The nitromethane derivatives are inhibitors of the enzyme aldose reductase and are of value in the treatment of certain complications of diabetes and galactosemia.
    Type: Grant
    Filed: April 28, 1989
    Date of Patent: April 7, 1992
    Assignee: Imperial Chemical Industries PLC
    Inventors: Steven P. Brown, Anthony L. Cooper, Jethro L. Longridge, Jeffrey Morris, John Preston